Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Down Following Analyst Downgrade

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares gapped down before the market opened on Thursday after Wall Street Zen downgraded the stock from a buy rating to a hold rating. The stock had previously closed at $35.74, but opened at $31.68. Collegium Pharmaceutical shares last traded at $31.7870, with a volume of 139,638 shares changing hands.

Several other equities analysts also recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Piper Sandler reaffirmed a “neutral” rating and set a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday. Finally, Needham & Company LLC lowered their price target on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $52.60.

Collegium Pharmaceutical News Roundup

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Second-quarter adjusted EPS was $1.92, above analyst expectations of approximately $1.72, while revenue increased 6.3% year over year to $199.9 million. Adjusted EBITDA rose 8% to $113.8 million and operating cash flow was $71.3 million. Collegium Pharmaceutical Q2 Earnings Beat
• Positive Sentiment: The ADHD portfolio showed momentum: JORNAY PM revenue climbed 41% to $46.1 million, and the completed AZSTARYS acquisition contributed $12.9 million in partial-quarter revenue. Collegium raised its full-year AZSTARYS revenue outlook to $65 million-$75 million from $60 million-$70 million, potentially supporting longer-term growth. Collegium Q2 2026 Results
• Neutral Sentiment: Piper Sandler reaffirmed its “neutral” rating but lowered its price target to $43 from $45. Needham retained a “buy” rating while cutting its target to $46 from $56, reflecting continued upside but greater near-term caution. Analyst Price Target Updates
• Negative Sentiment: Collegium reduced full-year product-revenue guidance to $825 million-$855 million from $865 million-$895 million and lowered adjusted EBITDA guidance to $445 million-$470 million from $475 million-$500 million. The company cited lower pricing and weaker-than-expected authorized-generic Nucynta revenue.
• Negative Sentiment: The pain portfolio declined 9% year over year to $140.9 million; Nucynta revenue fell 24% and Xtampza ER revenue dropped 14%. GAAP results also shifted to a $15.1 million net loss from $12.0 million of net income, while operating expenses increased 45%, adding pressure to profitability. Collegium Sales and Guidance Report

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in Collegium Pharmaceutical during the 2nd quarter valued at approximately $196,972,000. Rubric Capital Management LP boosted its holdings in Collegium Pharmaceutical by 5.3% in the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock worth $93,374,000 after acquiring an additional 157,743 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Collegium Pharmaceutical by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock worth $104,465,000 after acquiring an additional 29,876 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Collegium Pharmaceutical by 26.0% in the first quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock worth $60,358,000 after acquiring an additional 377,073 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Collegium Pharmaceutical by 1.1% in the fourth quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock worth $74,883,000 after acquiring an additional 18,160 shares during the last quarter.

Collegium Pharmaceutical Price Performance

The company has a quick ratio of 1.62, a current ratio of 1.14 and a debt-to-equity ratio of 3.50. The firm has a fifty day moving average price of $34.78 and a two-hundred day moving average price of $37.07. The stock has a market capitalization of $955.71 million, a P/E ratio of 23.77 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. The firm had revenue of $199.88 million during the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.Collegium Pharmaceutical’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.68 EPS. On average, analysts expect that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.